Based on 1 analyst offering 12 month price targets for Standard Biotools Inc
Min Forecast
$2.50+77.3%
Avg Forecast
$2.50+77.3%
Max Forecast
$2.50+77.3%
Should I buy or sell LAB stock?
Based on 1 analyst offering ratings for Standard Biotools Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LAB's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates LAB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More
Be the first to know when Wall Street analysts revise their LAB stock forecasts and price targets.
LAB stock forecasts by analyst
Analyst / Firm
Rating
Action
Price Target
Upside/Downside
Date
Analyst Color
locked
locked
$00.00
+00.00%
2024-10-31
1 of 1
Forecast return on equity
Is LAB forecast to generate an efficient return?
Company
N/A
Industry
-9.83%
Market
222.65%
Forecast return on assets
Is LAB forecast to generate an efficient return on assets?
Company
N/A
Industry
10.67%
LAB earnings per share forecast
What is LAB's earnings per share in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.24
LAB revenue forecast
What is LAB's revenue in the next 1 years based on estimates from 2 analysts?
Is Standard Biotools Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: LAB) stock is to Strong Buy LAB stock.
Out of 1 analyst, 1 (100%) are recommending LAB as a Strong Buy, 0 (0%) are recommending LAB as a Buy, 0 (0%) are recommending LAB as a Hold, 0 (0%) are recommending LAB as a Sell, and 0 (0%) are recommending LAB as a Strong Sell.
What is LAB's earnings growth forecast for 2025-2025?
(NASDAQ: LAB) Standard Biotools's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 46.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 65.95%.
Standard Biotools's earnings in 2025 is -$170,603,000.
In 2025, LAB is forecast to generate -$89,342,112 in earnings, with the lowest earnings forecast at -$89,342,112 and the highest earnings forecast at -$89,342,112.
What is LAB's revenue growth forecast for 2025-2025?
(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of 17.32% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 19.67%.
Standard Biotools's revenue in 2025 is $155,902,000.
In 2025, LAB is forecast to generate $68,086,134,154 in revenue, with the lowest revenue forecast at $67,304,390,678 and the highest revenue forecast at $68,867,877,630.
What is LAB's forecast return on assets (ROA) for 2025-2026?
(NASDAQ: LAB) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 10.67%.
What is LAB's Price Target?
According to 1 Wall Street analyst that have issued a 1 year LAB price target, the average LAB price target is $2.50, with the highest LAB stock price forecast at $2.50 and the lowest LAB stock price forecast at $2.50.
The Wall Street analyst predicted that Standard Biotools's share price could reach $2.50 by Oct 31, 2025. The average Standard Biotools stock price prediction forecasts a potential upside of 77.3% from the current LAB share price of $1.41.
What is LAB's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: LAB) Standard Biotools's current Earnings Per Share (EPS) is -$0.71. In 2025, LAB's EPS is forecast to hit -$0.24 (min: -$0.24, max: -$0.24).
What is LAB's forecast return on equity (ROE) for 2025-2026?
(NASDAQ: LAB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.